Light Sciences CEO steps down as company awaits results

As Light Sciences Oncology waits for clinical trial results, its CEO has moved on to another job. No interim CEO has been named, and the company has not commented on the departure.

Xconomy broke the news after Llew Keltner personally confirmed his departure to Luke Timmerman. The company, which is privately held, does not have to release its Phase III results for its unique cancer therapy, combining drugs and devices to eliminate solid tumors. Light Sciences CFO Bob Littauer told Timmerman that the company has not done the necessary statistical analysis of the trial results yet.

Light Sciences' approach uses a disposable catheter to inject talaporfin sodium directly into a solid tumor. The drug is activated by a light diode, killing the tumor without affecting healthy tissue nearby.

- read the Xconomy story
- and here's TechFlash's item

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.